ERBB2 and breast carcinoma: Indeed, trastuzumab, which is a humanized anti-HER2 antibody, is the first HER2-targeted therapeutic monoclonal antibody approved by the FDA in 1998 for the therapy of metastatic HER2+ breast cancer (Rossi et al., 2016; Shu et al., 2020).